Drugs / MGMTP140K-encoding retroviral vector
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01269424 Comparator | Nov 2011 → Dec 2020 | glioblastoma | Stanton Gerson MD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MGMTP140K-encoding retroviral vector | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01269424 ↗ |
| Target | MGMT | “expressing P140K MGMT” NCT01269424 ↗ |